HER2 inhibition: from discovery to clinical practice.
نویسنده
چکیده
In this issue of Clinical Cancer Research, Buzdar et al. (1) report on the success of trastuzumab, a humanized monoclonal antibody against the proto-oncogene HER2 (c-erbB2, HER-2/ neu), when administered with 5-fluorouracil, epirubicin, and cyclophosphamide (FEC) and paclitaxel chemotherapy, with high pathologic complete remission rates. These results are consistent with recent data presented by large multicenter trials, confirming the high efficacy of trastuzumab in women with early stage breast cancer.
منابع مشابه
Identification of Prognostic Genes in Her2-enriched Breast Cancer by Gene Co-Expression Net-work Analysis
Introduction: HER2-enriched subtype of breast cancer has a worse prognosis than luminal subtypes. Recently, the discovery of targeted therapies in other groups of breast cancer has increased patient survival. The aim of this study was to identify genes that affect the overall survival of this group of patients based on a systems biology approach. Methods: Gene expression data and clinical infor...
متن کاملThe HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy
Human epidermal growth factor receptor 2 (HER2) is overexpressed in around 20-30% of breast cancer tumors. It is associated with a more aggressive disease, higher recurrence rate, and increased mortality. Trastuzumab is a HER2 receptor blocker that has become the standard of care for the treatment of HER2 positive breast cancer. The effectiveness of Trastuzumab has been well validated in resear...
متن کاملPolyclonal Antibody against Different Extracellular Subdomains of HER2 Induces Tumor Growth Inhibition in vitro
Background: Human epidermal growth factor receptor 2 (HER2) has a crucial role in several malignancies. The extracellular domain of HER2 (HER2-ECD) has been extensively employed as an important target in passive and active immunotherapy. Isolated recombinant prokaryotic HER2-ECD subdomains were previously found to be ineffective in inducing anti-tumor antibody response. Objective: To employ rec...
متن کاملHER2 Dimerization Inhibitor Pertuzumab - Mode of Action and Clinical Data in Breast Cancer.
The humanized monoclonal antibody pertuzumab prevents the dimerization of HER2 with other HER receptors, in particular the pairing of the most potent signaling heterodimer HER2/HER3, thus providing a potent strategy for dual HER2 inhibition. It binds to the extracellular domain of HER2 at a different epitope than trastuzumab. Pertuzumab and trastuzumab act in a complementary fashion and provide...
متن کاملRisks from ionizing radiation during pregnancy
Gholami M1, Abedini MR2, Khossravi HR3, Akbari S4 1. Instructor, Department of medical physics, Faculty of medicine, Lorestan University of medical sciences 2. Assistant professor, Department of radiology, Faculty of medicine, Lorestan University of medical sciences 3. Assistant professor, Department of radiation protection, Iranian Atomic Energy Organization 4. Assistant professor, D...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Clinical cancer research : an official journal of the American Association for Cancer Research
دوره 13 1 شماره
صفحات -
تاریخ انتشار 2007